ValuEngine upgraded shares of Sientra (NASDAQ:SIEN) from a sell rating to a hold rating in a research report sent to investors on Saturday.
A number of other analysts have also weighed in on SIEN. BidaskClub lowered Sientra from a hold rating to a sell rating in a report on Thursday, December 7th. Zacks Investment Research upgraded Sientra from a sell rating to a hold rating in a report on Tuesday, January 2nd. Canaccord Genuity restated a buy rating and set a $19.00 target price on shares of Sientra in a report on Friday, January 5th. Stifel Nicolaus upgraded Sientra from a hold rating to a buy rating and set a $14.00 price objective for the company in a report on Friday, January 19th. Finally, Lake Street Capital lowered Sientra from a buy rating to a hold rating and decreased their price objective for the company from $15.00 to $11.00 in a report on Wednesday, February 21st. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The stock currently has an average rating of Hold and an average price target of $13.20.
Shares of Sientra (NASDAQ SIEN) opened at $10.45 on Friday. The firm has a market capitalization of $199.58, a price-to-earnings ratio of -3.13 and a beta of -1.10. Sientra has a twelve month low of $7.20 and a twelve month high of $16.68.
Sientra (NASDAQ:SIEN) last posted its earnings results on Tuesday, March 13th. The medical instruments supplier reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.21). The company had revenue of $11.10 million for the quarter, compared to analysts’ expectations of $11.90 million. Sientra had a negative return on equity of 107.35% and a negative net margin of 175.22%. The firm’s quarterly revenue was up 70.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.43) EPS. analysts forecast that Sientra will post -2.68 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently modified their holdings of the company. Nationwide Fund Advisors lifted its holdings in shares of Sientra by 260.4% during the 2nd quarter. Nationwide Fund Advisors now owns 10,963 shares of the medical instruments supplier’s stock valued at $107,000 after purchasing an additional 7,921 shares during the last quarter. New York State Common Retirement Fund purchased a new stake in shares of Sientra during the 2nd quarter valued at $148,000. Dimensional Fund Advisors LP lifted its holdings in shares of Sientra by 23.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 18,660 shares of the medical instruments supplier’s stock valued at $181,000 after purchasing an additional 3,534 shares during the last quarter. Parametric Portfolio Associates LLC lifted its holdings in shares of Sientra by 23.0% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 20,180 shares of the medical instruments supplier’s stock valued at $196,000 after purchasing an additional 3,770 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in shares of Sientra by 175.2% during the 3rd quarter. Wells Fargo & Company MN now owns 22,903 shares of the medical instruments supplier’s stock valued at $353,000 after purchasing an additional 14,582 shares during the last quarter. Hedge funds and other institutional investors own 77.38% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/03/21/sientra-sien-upgraded-to-hold-at-valuengine.html.
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.